Philips: angioplasty data reveals no safety concerns
(CercleFinance.com) - Four-year data from patients has revealed no safety concerns for Philips' drug-coated angioplasty balloon, the Dutch health technology company said on Monday.
The results showed no difference in mortality between patients treated with Philips' Stellarex and those treated with percutaneous angioplasty, the current standard of care, the group said in a statement.
The meta-analysis found that over four years, there was no significant difference in survival amongst patients treated with the Stellarex (85.7%) compared to those treated with PTA (85.6%), Philips pointed out.
Philips' technology is unlike any other drug-coated balloon for the treatment of peripheral artery disease, as it enables a low therapeutic drug dose.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The results showed no difference in mortality between patients treated with Philips' Stellarex and those treated with percutaneous angioplasty, the current standard of care, the group said in a statement.
The meta-analysis found that over four years, there was no significant difference in survival amongst patients treated with the Stellarex (85.7%) compared to those treated with PTA (85.6%), Philips pointed out.
Philips' technology is unlike any other drug-coated balloon for the treatment of peripheral artery disease, as it enables a low therapeutic drug dose.
Copyright (c) 2020 CercleFinance.com. All rights reserved.